Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children
EMHJ-Eastern Mediterranean Health Journal. 1999; 5 (5): 922-932
em Inglês
| IMEMR
| ID: emr-156683
ABSTRACT
In 1992, Egypt adopted a hepatitis B vaccine schedule at 2, 4 and 6 months of age. We evaluated the long-term immunogenicity and efficacy of vaccination using this schedule in 180 children whose time lapse since last vaccination varied between 1 month and 5 years. None of the participants had clinical hepatitis, HBsAg was not detected in any participant and all but one had negative results for anti-HBc test. Although a high seroprotection rate [93.3%] was elicited 1 month after vaccination, there were low initial anti-HBs concentrations and both declined rapidly over time. Thus, the short interval [2 months] between the second and third doses of vaccine is less desirable in the long term. We recommend booster inoculations for all previously vaccinated children and a new vaccination schedule at 1, 2 and 9 months
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Fatores de Tempo
/
Vacinas Sintéticas
/
Pré-Escolar
/
Estudos Transversais
/
Esquemas de Imunização
/
Imunização Secundária
/
Anticorpos Anti-Hepatite B
/
Antígenos do Núcleo do Vírus da Hepatite B
/
Antígenos de Superfície da Hepatite B
Tipo de estudo:
Estudo de prevalência
Limite:
Feminino
/
Humanos
/
Lactente
/
Masculino
Idioma:
Inglês
Revista:
East Mediterr Health J.
Ano de publicação:
1999
Similares
MEDLINE
...
LILACS
LIS